Kumar Neil

Kumar Neil, CEO of an undisclosed company, has demonstrated a consistent pattern of selling shares in BridgeBio Pharma (BBIO), with no recorded purchases across 106 transactions totaling $55.5 million in sales. Recent SEC Form 4 filings reveal an accelerated divestment trend, with 18 sales in early 2026 alone. Between February and March 2026, Neil executed multiple high-value disposals, including a $2.33 million transaction on February 16 and a cluster of sales on March 12–13 exceeding $4.1 million collectively. The largest single sale during this period occurred on February 19, valued at $1.34 million, while smaller transactions—such as a $21,045 sale the same month—suggest partial liquidation. Notably, all activity centers on BBIO, with no trades in Maze Therapeutics (MAZE) beyond a single transaction coded as a derivative adjustment on March 27, 2026, carrying no reported value. The absence of any buy transactions—both historically and in recent months—indicates a one-directional approach to equity management. While the filings document routine sales across varying amounts, from six-figure disposals to smaller increments, they reflect no acquisition activity or diversification into other securities. The consistency of these transactions, particularly their concentration in a short timeframe, underscores a sustained reduction in Neil’s BBIO holdings without offsetting positions.